论文部分内容阅读
20例患者均为1991年1月至1993年7月接受雄激素(达那唑或氟烃甲基睾丸素)治疗的低危MDS患者(原始细胞≤10％),且血小板数<50×10~9/L。其中,难治性贫血(RA)11例,难治性贫血伴铁粒幼细胞增多(RARS)1例,难治性贫血伴幼稚细胞增多(RAEB)7例,慢性粒单核细胞白血病(CMML)1例;15例有贫血,7例依赖输血,13例中性粒细胞数<1.5×10~9/L。从诊断到接受治疗的间隔时间中位数6个月(1～50个月),接受雄激素治
All 20 patients were low-risk patients with MDS (≤10% of blasts) treated with androgen (danazol or fluorocarbon methyltestosterone) from January 1991 to July 1993 and had a platelet count <50 × 10 ~ 9 / L. Among them, 11 cases were refractory anemia (RA), 1 cases were refractory anemia with increased myeloid cell count (RARS), 7 cases were refractory anemia with increased naive cells (RAEB), 8 cases were chronic myelomonocytic leukemia ) In 1 case; anemia in 15 cases, blood transfusion in 7 cases, and neutrophil count in 13 cases <1.5 × 10 ~ 9 / L. The median interval from diagnosis to treatment was 6 months (1 to 50 months), and androgen treatment